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1  | INTRODUC TION
Psoriasis is one of the most common chronic inflammatory skin 
disorders, affecting 2%- 3% of the Caucasian population with 
unquestionable negative impacts on quality of life. Characterisation 
is complicated by the multifactorial origin of the disease, as the 
interplay of genetic and environmental factors has great influ-
ence on the formation of psoriatic lesions. It is well established 
that innate and adaptive immunological processes both interact in 
disease pathogenesis.[1-3] Recent findings indicate that activation 
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Abstract
In our recent cDNA microarray experiment, three SR- rich splicing factors—SFRS18, 
PPIG and LUC7L3—were shown to exert altered responsiveness upon T- lymphokine 
stimulation of psoriatic non- involved and healthy epidermis samples. We have also 
demonstrated that double silencing LUC7L3 and SFRS18 efficiently decreased pro-
duction of the psoriasis- associated EDA+ fibronectin isoform. These findings 
prompted the further investigation of signalling pathways affected by LUC7L3 and 
SFRS18. To detect gene expression and splicing pattern alterations upon double si-
lencing of LUC7L3 and SFRS18 in an HPV- immortalised keratinocyte cell culture, 
paired- end RNA sequencing was carried out. Marked changes in exon usage were 
revealed, in contrast to the modest alterations detected in gene expression, provid-
ing a closer delineation of the potential targets of the examined splicing factors. The 
most prominent gene expression change was detected for IFI6, an interferon- 
inducible gene highly expressed in psoriasis. Interacting partners of IFI6 and certain 
psoriasis- associated transcripts also exhibited significantly increased expression 
upon silencing. In addition to elevated abundance of the EDA+ fibronectin interactor 
ITGA5, we confirmed decreased EDA domain inclusion, which agrees well with our 
prior experimental data. Furthermore, differential exon usage was established for 
the transcription element CREB1, along with HERC6 and CUL1, which are implicated 
in ubiquitination. Although immortalised keratinocytes express low levels of TINCR, 
a long non- coding RNA involved in terminal differentiation of keratinocytes, splicing 
alterations were successfully demonstrated for this RNA as well. We believe that the 
targeted investigation of mRNA maturation disturbances may help us gain deeper 
insight into the molecular pathogenesis of psoriasis.
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of plasmacytoid dendritic cells could be a determinant step in the 
initiation phase of psoriasis, which is triggered by the complexes 
of cathelicidin (LL37) and the self- DNA/RNA of stressed kerati-
nocytes.[3-6] This step is followed by the release of type I interfer-
ons, as well as the consecutive production of other inflammatory 
mediators, such as IL- 1β, IL- 6 and TNFα, which are activators of 
myeloid dermal dendritic cells.[3,6,7] This cell type is an important 
source of IL- 12 and IL- 23, which are cytokine products that stimu-
late multiple T- cell lineages implicated in further pathogenic steps, 
including Th1, Th17 and Th22 lymphocytes.[1,3,7,8] Different stages 
of the disorder are characterised by unique cytokine profiles: 
whereas the primary phase is dominated by Th1 cells, the propa-
gation of the disorder entails increasing involvement of the Th17 
pathway.[3,9] Besides the above- mentioned molecular pathways, 
we should also mention the involvement of further contributors, 
including the regulation of antimicrobial defense pathways, lipid 
metabolism and fatty acid metabolism, Wnt- signalling pathway and 
IL10 family cytokines, which are implicated to play crucial roles 
in disease development.[10-18] Related members of the IL- 36 fam-
ily, including IL37 and IL38, have also been investigated in detail 
in the context of psoriasis.[17-19] Despite the wealth of data, our 
knowledge regarding the complexity of molecular mechanisms in 
psoriasis is still incomplete, and further experiments are needed 
for the detailed description of the molecular background of this 
inflammatory skin disorder.
In recent years, large- scale gene expression studies have become 
more accessible and several studies have been conducted to describe 
gene expression differences in healthy, psoriatic non- involved and 
involved epidermis.[13,20-22] The majority of these studies, however, 
investigated steady- state gene expression levels of various patient- 
derived samples. In contrast to previous works, we recently inves-
tigated T- lymphokine- induced gene expression changes between 
healthy and psoriatic non- involved epidermis in a cDNA microarray 
experiment.[23] In our experimental setup, organotypic skin cultures 
were generated, and half of the samples, both healthy and non- 
involved epidermis, were treated with a T- lymphokine mixture con-
taining IFN- γ, IL3 and GM- CSF. This T- lymphokine combination has 
been shown to facilitate the proliferation of keratinocyte precursors 
in psoriatic non- involved epidermis; thus, it is likely that these cyto-
kines are important participants of early disorder development.[24]
When comparing T- lymphokine- induced gene expression be-
tween healthy and psoriatic epidermis, three SR- rich splicing fac-
tors—arginine/serine- rich 18 (SFRS18), peptidyl- prolyl cis- trans 
isomerase G (PPIG) and luc- 7 like protein 3 (LUC7L3)—were found 
to be differentially regulated in healthy and non- involved psori-
atic keratinocytes. SR proteins, which contain a serine/arginine- 
rich domain and at least one domain for RNA binding, are the 
trans- regulators of mRNA maturation. Usually—although not 
exclusively—they bind to enhancer elements and promote exon 
inclusion.[25,26] The finding is notable, as only a few articles con-
cerning psoriasis and mRNA maturation have been published: we 
and others have shown that, compared to the healthy samples, the 
fibronectin isoform containing extra domain A (EDA+ fibronectin) 
is overexpressed in psoriatic non- involved epidermis and modifies 
the response of keratinocytes to T- lymphokine stimuli.[27-29] The 
EDA domain of fibronectin belongs to the type III repetitive mod-
ules and is encoded by exon 33 of the fibronectin (FN1) gene.[30-33] 
In subsequent experiments, we successfully verified that the afore-
mentioned splicing regulators are able to facilitate EDA domain in-
clusion. Data mining using publicly available interaction databases 
also supported the credibility of the interaction of LUC7L3 and 
SFRS18 splicing regulators.[34] These data suggest that these splic-
ing factors indeed contribute to disease pathogenesis and their 
effect is—at least partially—mediated by the regulation of psoriasis- 
associated EDA+ fibronectin.
In this study, we aim to determine additional molecular pathways 
influenced by the SR- rich splicing regulators, LUC7L3 and SFRS18, 
as the combined effects of these two genes proved to be the most 
potent in prior experiments.[34] Global transcriptome analysis was 
performed using pair- end RNA- Sequencing (RNA- Seq) to define 
gene expression changes and differential exon usage in human pap-
illomavirus (HPV)- immortalised keratinocytes.
2  | MATERIAL S AND METHODS
2.1 | Culturing of HPV- KER cells
As we described previously, HPV- KER cell line was prepared by 
immortalisation with HPV E6 oncogene.[35] HPV- immortalised ke-
ratinocytes were grown in 75 cm2 cell culture flasks at 37°C in a 
humidified atmosphere containing 5% CO2. For the maintenance 
of the cultures, keratinocyte serum- free medium was used (Gibco® 
Keratinocyte SFM Kit; Life Technologies, Copenhagen, Denmark), 
supplemented with 1% L- glutamine (PAA, Pasching, Austria) and 
1% antibiotic/antimycotic solution (PAA). The medium was changed 
every 2 days.
2.2 | Gene- specific silencing
HPV- KER cells were transiently transfected with gene- specific siR-
NAs at approximately 70% confluency. Transfection medium and 
reagents were obtained from Santa Cruz Biotechnology (Dallas, TX, 
USA). In our siRNA- mediated silencing experiments, scrambled and 
gene- specific LUC7L3 and SFRS18 siRNA duplexes were used. The 
most effective silencing results were obtained in serum- free cul-
ture medium without additive and supplements. Real- time RT- PCR 
was used to confirm the effectiveness of silencing. Quality control 
of samples submitted to RNA- Seq was carried out by Bioanalyzer 
(Agilent, Santa Clara, CA, USA), and the measurements indicated ex-
cellent RNA quality (RIN: 10).
2.3 | Sequencing
Libraries were prepared with cDNA using the Illumina- compatible 
ScriptSeq RNA- Seq Library Preparation Kit (Epicenter) for 
2 × 100 bp paired- end library construction, for two technical 
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replicates per condition (silenced and control). Sequencing was car-
ried out on the Illumina HiScan SQ platform, resulting in an average 
depth of ~35 million raw reads per sample. Library preparation and 
sequencing were carried out in the Center for Clinical Genomics and 
Personalized Medicine, University of Debrecen.
2.4 | Statistical analysis and bioinformatics
Raw reads in FASTQ format were submitted to quality control using 
FASTQC, followed by quality and adapter trimming using the fastx 
toolkit. Filtered reads were mapped to the Hg19 human reference 
with the STAR aligner, using parameters optimised for splice- site 
discovery.[36] In silico contaminant screening was also carried out, 
and ambiguously mapping reads were discarded from further analy-
sis. Potential fusion transcripts were predicted by TopHat2 using 
the fusion- search algorithm.[37] Following mapping, transcript as-
sembly and annotation were carried out using Cufflinks, and read 
counts were summarised at the gene and exon levels using htseq- 
count.[38,39] Count data were then processed using the DESeq and 
DEXSeq packages to quantify differential gene expression and dif-
ferential exon usage, respectively.[40] Exons with a coverage <5 reads 
were discarded from the analysis. Functional annotation of differen-
tially expressed genes was carried out using Gene Ontology (GO) en-
richment, and extensive comparisons with previous literature- based 
gene sets and data visualisation were carried out in R version 3.0.1, 
and Cytoscape.
2.5 | Real- time RT- PCR
Using the iScript TM cDNA Synthesis kit (#1708891, Bio- Rad, 
Hercules, CA), 1 mg total RNA purified from HPV- KER cells was re-
verse transcribed. Subsequently, real- time RT- PCR was carried out 
using custom primer sets and the Universal Probe Library (Roche, 
Basel, Switzerland) with an iQ Supermix (#1708862, Bio- Rad, 
Hercules, CA) to quantify transcript abundance. Relative gene ex-
pression data were calculated by the ΔΔCt method, normalising the 
expression to the 18S ribosomal RNA.
2.6 | PCR
Samples were collected from the siRNA- silenced HPV- KER cell 
cultures, and total RNA was isolated using the TRIzol® Reagent 
(Invitrogen Corp., Carlsbad, CA, USA), according to the instruc-
tions of the manual. cDNA synthesis was performed with the iScript 
cDNA Synthesis Kit (Bio- Rad Laboratories, Hercules, CA, USA) from 
1 μg total RNA. To amplify a 847- bp product from EDA– fibronec-
tin and a 1221- bp product from EDA+ fibronectin, specific primers 
were used with PCR conditions summarised in Szell et al (2004). 
Semiquantitative analysis of the differentially spliced fibronec-
tin isoforms is also described in the referred paper. Amplification 
products (10 μL) were size fractionated on a 1% agarose gel at 90 V. 
Image acquisition and analysis were carried out on a Bio- Rad GelDoc 
XR densitometer.
3  | RESULTS
Immortalised HPV- KER cells in which both the LUC7L3 and SFRS18 
splicing regulators were silenced were subjected to RNA- Seq profiling. 
Silencing efficiencies, determined by qPCR prior to sequencing, were 
between ~70%- 80% (Figure S1). Following read mapping to reference 
Hg19, de novo transcript assembly was performed to identify the po-
tentially novel transcripts and isoforms in the HPV- KER cell line, as well 
as to provide accurate exon- level annotation for downstream analy-
ses. To assess the alterations caused by the dual silencing of the splic-
ing factors, differential expression and differential exon usage metrics 
were generated, allowing the complexity and possible errors intro-
duced by isoform reconstruction methods to be circumvented.[41,42]
3.1 | Differential gene expression
As expected from the experimental model, combined silencing of the 
LUC7L3 and SFRS18 splicing factors resulted in moderate changes in 
gene expression (Figure S2), accompanied by extensive disturbances 
in exon inclusion and exclusion rates. As a result, 35 protein- coding 
genes were identified as differentially expressed (logFC > 0.5, 
FDR < 0.05), with IFI6 and MX1, ISG15 and KRT6A mRNAs show-
ing the most robust fold- changes. Notably, the majority of these 
regulated genes share functions related to type I interferon signal-
ling based on enrichment analysis. The most significant enriched GO 
terms were cellular response to type I interferon, cellular response 
to cytokine stimulus (GO:0071345) and regulation of viral genome 
replication (GO:0045069); these functions were also identified 
in the functional interaction network based on the Reactome and 
GeneMania databases (Figure 1A). Independent qPCR validation of 
IFI6 expression indicated up to fourfold changes, which agrees well 
with our high- throughput results (Figure 1B).
3.2 | Differential exon usage
Differential exon usage was measured for the assembled transcript 
models, and detected in 224 exons of 217 genes at logFC > 0.5, 
FDR < 0.1, corresponding to P- value < 7 × 10-4. It is notable that 
differential usage of multiple exons per gene was detected for a 
considerable number of genes throughout the dataset, possibly in-
dicating fine- tuned changes induced by silencing. Differential exon 
usage was detected in several non- coding RNAs, whereas functional 
network analysis of the most significant genes indicted an exten-
sive co- expression background, suggesting overlapping regulation 
at the transcriptional and post- transcriptional levels (Figure 2). 
Transcripts regulated with regard to splicing pattern alterations did 
not exhibit extensively shared molecular functions, in contrast to 
regulation detected at the gene expression level. Notably, mining of 
co- expression- level databases resulted in the identification of abun-
dant relations between regulated genes, indicating their coordinated 
transcriptional regulation, and, as supported by our current dataset, 
possibly shared post- transcriptional processing events. The result-
ing complete functional network contained 172 genes, with only 4 
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disconnected nodes, and an average node connectivity degree of 
13.4. Most connecting edges corresponded to co- expression, fol-
lowed by physical and genetic interactions. The core set of the most 
highly connected genes is presented in Figure 3.
Experimental validation of fibronectin exon usage was also car-
ried out on the scrambled controls and siRNA- silenced samples of 
the RNA- Seq experiment. RT- PCR using exon- specific, junction- 
spanning primers for fibronectin transcripts, followed by visualisa-
tion with agarose gel electrophoresis, indicated significantly altered 
inclusion of exon 33 (encoding the EDA domain) and the decreased 
relative abundance of the EDA+ isoform (Figure 4).
4  | DISCUSSION
In recent years, next- generation sequencing- based gene expression 
profiling techniques, such as RNA- Seq, have revolutionised psoria-
sis research. RNA- Seq possesses a wider dynamic range compared 
to microarrays and permits the investigation of potentially novel 
F IGURE  2 DEXSeq differential exon usage plots of selected 
transcripts showing significant alterations (logFC > 0.5, FDR < 0.1). 
Red: average exon usage frequency in control samples; blue: 
average exon usage frequency in treated samples; and pink: 
significantly differentially expressed exons. De novo assembled 
transcript diagrams depicted in bottom rows
F IGURE  3 Subnetwork representation of a functional network 
constructed from genes exhibiting significant exon usage changes, 
with edge colour corresponding to GeneMania and Reactome 
annotation categories
F IGURE  1 Functional network of significantly differentially 
expressed genes (log2FC > 0.5, FDR < 0.05) in response to dual 
silencing of LUC7L3 and SFRS18, with edges corresponding to 
GeneMania and Reactome annotation categories (A). qRT- PCR 
validation of IFI6 expression changes in siRNA- silenced samples; 
columns present the mean of three independent experiments. 
P < .05 was considered as statistically significant (B). *P < .05; 
**P <.01; ***P < .001.
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transcripts, non- coding RNAs and different splicing isoforms.[43-47] 
Nonetheless, only a few psoriasis studies to date address differential 
exon usage or altered expression of RNA isoforms.[17,45,47]
LUC7L3 and SFRS18 splicing factors have been selected based 
on the results of the aforementioned cDNA microarray experi-
ment, where we identified genes showing T- lymphokine- induced 
differential expression among control and psoriatic non- involved 
epidermis.[23,34] Products encoded by LUC7L3 and SFRS18 genes 
are both SR- rich splicing regulators. LUC7L3—which has a strong 
sequence similarity with yeast U1 snRNP component Luc7p—has 
also been shown to participate in the cisplatin- induced resistance 
of tumor cells.[48,49] Another report suggests LUC7L3 protein bind-
ing to the cAMP- responsive element, and a recent article claimed 
antiviral property for this splicing regulator.[50,51] Relatively few 
data are available for SFRS18. Zimowska and Lin et al reported in-
teraction of the cell adhesion and splicing protein pinin (PNN) and 
SFRS18.[52,53]
The main purpose of the present study was to determine differential 
gene expression and exon usage upon altered expression of LUC7L3 
and SFRS18. In agreement with our primary hypothesis, the extent of 
gene expression changes was relatively moderate; in contrast, several 
significant alterations in differential gene expression were induced by 
the siRNA transfection. Among these data, the most pronounced change 
was observed for IFI6 (also known as G1P3), an interferon- stimulated 
gene (ISG), which mediates anti- inflammatory, antiviral and antiprolifer-
ative effects of interferons. IFI6 is a member of the human ISG12 family, 
which also includes ISG12A (IFI27), ISG12B and ISG12C. In contrast 
to other ISG12 isoforms, IFI6 was demonstrated to possess an antia-
poptotic feature.[54] In addition to its involvement in cancer, biological 
function of IFI6 in psoriasis pathogenesis has also been reported.[54,55] 
Based on the previous results of our research group, IFI6 might contrib-
ute to keratinocyte survival due to its antiapoptotic effect. Experimental 
data suggest elevated IFI6 gene expression both in the psoriatic non- 
involved and involved epidermis as compared to the healthy samples.[55] 
Gene expression changes of IFI6 have been successfully validated, ex-
hibiting up to ~fourfold elevation in expression. In addition, we demon-
strated increased levels of the ISG12 (IFI27) mRNA, also implicated in 
psoriasis.[56] Thus, LUC7L3/SFRS18 might contribute to balancing pro- 
and antiapoptotic events.
Furthermore, several predicted interactors for IFI6 (https://
string-db.org/cgi/network.pl?taskId=Mq3bitC7x2Bp) exhibited sig-
nificant upregulation in the silenced cells. Of these predicted genes, 
we detected OAS1, OAS2, IFIT1, IFIT3, ISG15 and MX1, all of which 
are related to antiviral immunity.[57,58] The elevated expression 
of MX1, ISG15 and OAS2 in psoriatic skin samples has been veri-
fied in a previous experiment.[58] In a recent RNA- Seq experiment, 
Raposo and his co- workers found that 16 antiviral genes—including 
ISG15—showed at least twofold elevation in psoriatic epidermis.[58] 
OAS2 and another oligoadenylate synthetase, OAS3, have been 
shown to be elevated in psoriatic lesional skin in several previous 
transcriptome- wide studies.[17,45,59] We have also demonstrated 
LUC7L3/SFRS18- regulated expression of KRT6A and S100A9, which 
are known innate immunity- related molecules.[60,61]
In contrast to our results for differential gene expression, our inves-
tigation of differential exon usage indicated more robust alterations. 
The extracellular matrix protein fibronectin is one of the most suitable 
models for studying splicing events. The presence of the EDA domain is 
associated with intrauterine development, wound healing and cancer 
pathogenesis.[32,33] In addition, EDA+ fibronectin was demonstrated 
to be a putative factor modifying keratinocyte response to mitogenic 
signals.[28] In our previous work, we verified that, similarly to other 
SR- rich proteins (such as SF2/ASF), LUC7L3, PPIG and SFRS18 also 
facilitate inclusion of the EDA domain.[31,62,63] We were able to vali-
date the significant changes of EDA+/EDA– fibronectin abundances 
in our present large- scale experiment as well.[34] In addition to dif-
ferential splicing of fibronectin, we also demonstrated the significant 
upregulation of ITGA5, a fibronectin receptor. Data in the literature 
demonstrate that the presence of the EDA domain alters the bind-
ing features of fibronectin and increases its affinity for ITGA5.[31,64,65] 
Elevated levels of ITGA5 might be a compensatory mechanism against 
the decreased relative amount of EDA+ fibronectin.
LUC7L3, formerly designated CREAP- 1, is characterised by its bind-
ing domain for the cAMP regulatory element.[50] However, in addition 
to potential direct interaction with CRE, silencing of the splicing factors 
also alters the splicing pattern of CREB1. Thus, LUC7L3 potentially plays 
a modulatory role in this fundamental element of transcription: altered 
splicing might influence the protein binding of CREB1. Components of 
F IGURE  4 DEXSeq differential exon usage plot of fibronectin 
(FN1), showing the differential inclusion of exon 33, encoding 
the oncofetal EDA domain. Red indicates the average exon 
usage frequency in control samples and blue in silenced samples. 
Significantly differentially expressed exons are indicated in pink.  
(A) Independent qRT- PCR- based validation of differential exon 
usage, indicating abundance of alternative splicing variants in 
control (grey) and treated (black) samples in double replicates. 
Significance threshold: P < .05 (B)
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various cellular processes, such as CUL1, HERC1 and HERC6, were are 
also affected. CUL1 is a component of the E3 ubiquitin ligase complex 
and is overexpressed in melanoma, leading to hyperproliferation.[66] 
The HERC gene family is involved in multiple molecular processes, in-
cluding cell- cycle regulation, DNA repair and ubiquitination, and is also 
differentially regulated in psoriatic skin. HERC6 is indicated in E3 con-
jugation of ISG15.[67] OAS2, indicated in antiviral processes, exhibited 
marked gene expression upregulation as well as differential exon usage. 
Several genes with relatively sparse functional characterisation avail-
able in the current literature presented markedly altered exon usage. 
These include NBEAL1, AUH, with RNA binding and hydratase activi-
ties, and the HERC2 paralog RCC1.[68-70]
Differential exon usage for long non- coding RNAs has been de-
tected using RNA- Seq.[46] We have also detected lncRNAs with differ-
ential exon usage, most notably TINCR and NEAT1. The role of NEAT1 
is relatively well studied in tumorigenesis: its overexpression has been 
verified in lung, oesophagus, colorectal and hepatocellular carcinoma.[71] 
NEAT1 might also be involved in psoriasis, as keratinocyte hyperprolif-
eration is an elementary step in the pathogenesis. The widespread func-
tionality of TINCR lncRNA in keratinocyte maturation has been recently 
described: whereas another non- coding transcript, ANCR, is needed 
for the maintenance of keratinocyte precursors, TINCR helps terminal 
differentiation. In undifferentiated keratinocytes, TINCR is regarded as 
a low abundance transcript, whereas in differentiated keratinocytes, 
TINCR exhibited elevated expression.[72,73] Accordingly, we have also 
shown that TINCR is expressed at low levels in HPV- immortalised cells. 
Altered splicing patterns might affect TINCR binding capacity through 
the inclusion of one of its several “TINCR box” motifs.
In our present RNA- Seq experiment, we demonstrated that the 
LUC7L3 and SFRS18 splicing factors contribute to the regulation of 
several well- known psoriasis- associated pathways, including the IFN 
signalling pathway, antiviral immunity and ubiquitination. Regulatory 
roles of these SR- rich splicing factors have also been verified for fi-
bronectin mRNA maturation. These results, together with our re-
sults for long non- coding RNA expression and exon usage changes, 
might open new insights into molecular disturbances in early psoria-
sis development caused by altered mRNA maturation.
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FIGURE S1 Combined siRNA silencing of LUC7L3 and SFRS18 splic-
ing factors was the most effective for the alteration of EDA domain 
inclusion of fibronectin during mRNA maturation. The efficacy of si-
lencing was 83.6% ± 4.24 for LUCL73 and 70.1% ± 1.56 for SFRS18, 
in two replicates
FIGURE S2 Volcano plot of differentially expressed genes upon 
LUC7L3/SFRS18 double silencing. Dashed line indicates P- value 
cut- off = .001
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